Abstract: The present invention provides splice variants of myostatin that promote muscle growth, and include polynucleotides and polypeptide sequences, constructs comprising the sequences and compositions for regulating muscle growth and treating diseases associated with muscle tissue. The splice variants include the consensus sequence X1 I F L E X2 X3 X4 Q X5 C S I L X6 X7 X8 X9 X10 wherein X1 is I or L, X2 is V or L, X3 is Y, C, G or S, X4 is I or F, X5 is F or L, X6 is G or E, X7 is E or V, X8 is A or T, X9 is A or V and X10 is absent, F or L. The present invention also provides for the use of the present sequences in identifying animals with altered muscle mass, and for use in selective breeding programs to produce animals with altered muscle mass.
Type:
Grant
Filed:
April 12, 2011
Date of Patent:
June 4, 2013
Assignee:
Myostin Therapeutics Pty Ltd
Inventors:
Ferenc Jeanplong, Christopher David McMahon
Abstract: An isolated recombinant polypeptide having myostatin antagonist activity, comprising a C-terminally truncated mature myostatin peptide, wherein the C-terminal truncation is at a position at or between amino acids 281 and 329, or a fragment, variant or derivative thereof.
Type:
Grant
Filed:
August 2, 2007
Date of Patent:
November 13, 2012
Assignee:
Myostin Therapeutics Pty Ltd.
Inventors:
Ravi Kambadur, Mridula Sharma, Monica Senna Salerno De Moura, Carole J. Berry, Victoria Siriett, Robert Syndecombe Bower, Gina Diane Nicholas, Craig Desmond McFarlane